-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $320

Benzinga·05/02/2025 18:32:43
Listen to the news
RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Outperform and lowers the price target from $324 to $320.